SPC
ISEE

Slate Path Capital’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Slate Path Capital’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-430,000
Closed -$21.9M – 16
2016
Q2 		$21.9M Hold
430,000
– – 1.72% 11
2016
Q1 		$18.2M Buy
+430,000
New +$21.9M 1.41% 10

Other funds holding ISEE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
JCG
JHL Capital Group Chicago, Illinois $805M AUM 50.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TBC
Three Bays Capital Boston, Massachusetts $848M AUM 7.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Slate Path Capital's ISEE Position: Q3 2016 in Review

Slate Path Capital sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2016, closing a stake of 430,000 shares — an estimated $21.9M sold.

Slate Path Capital first reported a position in ISEE in Q1 2016 and held it in 2 quarters. The position peaked at $21.9M in Q2 2016. 191 funds tracked by Wall St. Rank hold ISEE as of Q3 2016.

  • Slate Path Capital reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Slate Path Capital sold 430,000 IVERIC bio, Inc. Common Stock shares in Q3 2016, an estimated $21.9M.
  • Slate Path Capital first reported a position in IVERIC bio, Inc. Common Stock in Q1 2016 and held it in 2 quarters.
  • Slate Path Capital's IVERIC bio, Inc. Common Stock position peaked at $21.9M in Q2 2016.
  • 191 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2016.

Based on Slate Path Capital's 13F filing for Q3 2016, filed 14 Nov 2016.